Model‐informed assessment of ethnic sensitivity and dosage justification for Asian populations in the global clinical development and use of cladribine tablets

• Published in: Clinical and translational science Vol. 15; no. 2; pp. 297 - 308
• Main Authors: Munafo, Alain, Terranova, Nadia, Li, Dandan, Liu, Ping, Venkatakrishnan, Karthik
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.02.2022; John Wiley and Sons Inc; Wiley
• Subjects: Asia - ethnology; Asian people; Biological Availability; Cell number; Cladribine; Cladribine - administration & dosage; Cladribine - pharmacokinetics; Clinical trials; Dosage; Dose-Response Relationship, Drug; Drug development; Drug dosages; Drug Interactions - ethnology; Drug therapy; Humans; Lymphocytes; Lymphocytes T; Multiple sclerosis; Patients; Pharmacodynamics; Pharmacokinetics; Phosphorylation; Population; Rare diseases; Review; Reviews; Sensitivity analysis; Tablets; Treatment Outcome; Asia; Hong Kong China; South Korea; Singapore; China; Taiwan
• ISSN: 1752-8054; 1752-8062; 1752-8062
• DOI: 10.1111/cts.13166

Cladribine tablets have been approved in many countries for the treatment of patients with various forms of relapsing multiple sclerosis (MS). Cladribine has a unique pharmacokinetic/pharmacodynamic (PK/PD) profile with a short elimination half‐life (~ 1 day) relative to a prolonged PD effect on specific immune cells (most notably a reversible reduction in B and T lymphocyte counts). This results in a short dosing schedule (up to 20 days over 2 years of treatment) to sustain efficacy for at least another 2 years. Global clinical studies were conducted primarily in White patients, in part due to the distinctly higher prevalence of MS in White patients. Given the very low prevalence in Asian countries, MS is considered as a rare disease there. In spite of the limited participation of Asian patients, to demonstrate favorable benefit/risk profile in the treatment of MS demanded application of a Totality of Evidence approach to assess ethnic sensitivity for informing regulatory filings in Asian countries and supporting clinical use of cladribine in Asian patients. Population PD modeling and simulation of treatment‐related reduction in absolute lymphocyte count, as a mechanism‐related biomarker of drug effect, confirmed consistent PDs in Asian and non‐Asian patients with MS, supporting absence of ethnic sensitivity and a common dosage across populations. Through this example, we demonstrate the value of holistic integration of all available data using a model‐informed drug development (MIDD) framework and a Totality of Evidence mindset to evaluate ethnic sensitivity in support of Asia‐inclusive development and use of the drug across populations.